Prurigo Nodularis

Nemolizumab has a rapid onset of action in prurigo nodularis, as represented by improvement in sleep and itch reduction within 48 hours of administration. Individuals with prurigo nodularis tend to experience multiple itchy nodules, sleep disturbances, and a poor quality of life. Nemolizumab is an interleukin 31 α receptor (IL-31AR) inhibitor that positively affects prurigo...

Treatment of prurigo nodularis patients with dupilumab produced statistically significant improvement in skin lesions and pruritus, according to a review of two clinical trials. Prurigo nodularis is characterized by chronic inflammation of the skin and the development of intensely pruritic nodules. There is inadequate evidence regarding the safety profile and treatment efficacy of dupilumab in...

A recent review confirmed the clinical effectiveness of dupilumab for treating prurigo nodularis, as represented by significant decreases in numeric rating scale itch intensity scores and high safety ratings in prurigo nodularis patients with no serious adverse events. The conventional therapeutic approaches in the management of prurigo nodularis have high side effect profiles and limited...

Compared to treatment with a placebo, patients with moderate to severe prurigo nodularis treated with nemolizumab demonstrated modulation of epithelial differentiation, inflammatory signaling, and neural development. Prurigo nodularis is a dermatological condition that involves hyperkeratotic skin nodules and intense pruritus. Nemolizumab is a monoclonal interleukin 31 receptor α antibody that represents a novel therapeutic strategy...

A recent study found that patients with prurigo nodularis had relatively greater abnormalities identified on metabolic, renal, hepatic, hematologic, and endocrine laboratory testing compared to healthy controls.  Prurigo nodularis is a chronic dermatological condition that is associated with different systemic comorbidities. The current medical literature lacks adequate evidence to support laboratory testing in the diagnosis...

For adults with prurigo nodularis (PN), dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13, demonstrates clinically meaningful and significant improvements in itch and skin lesions in two phase 3 trials (LIBERTY-PN PRIME and PRIME2), according to a study published online May 4 in Nature Medicine. Gil...